Cardiovascular Drugs Practice Questions

Q: Valsartan differs from ramipril in the following respect?

It does not potentiate bradykinin. **Explanation:** The core difference between **Valsartan** (an Angiotensin Receptor Blocker - ARB) and **Ramipril** (an ACE Inhibitor) lies in their mechanism of action regarding the kinin system. **1. Why Option A is correct:** ACE (Angiotensin-Converting Enzyme) is identical to **Kininase II**, the enzyme responsible for the degradation of **bradykinin**. * **Ramipril (ACEI):** Inhibits Kininase II, leading to increased levels of bradykinin. This accumulation is responsible for the classic side effects of dry cough and angioedema. * **Valsartan (ARB):** Directly blocks the $AT_1$ receptor without affecting the ACE enzyme. Therefore, it **does not potentiate bradykinin**, making it a preferred alternative for patients who develop a cough on ACE inhibitors. **2. Why other options are incorrect:** * **Option B:** Both ACEIs and ARBs are **contraindicated** in bilateral renal artery stenosis. They prevent $AT_2$-mediated vasoconstriction of the efferent arteriole, which can lead to a precipitous drop in GFR and acute renal failure. * **Option C:** Neither drug impairs carbohydrate tolerance. In fact, both classes are known to **improve insulin sensitivity** and are the drugs of choice for hypertensive diabetic patients due to their nephroprotective effects. * **Option D:** Both ACEIs and ARBs are **teratogenic** (Category X). They have significant fetopathic potential, causing fetal renal anomalies, oligohydramnios, and skull hypoplasia. **Clinical Pearls for NEET-PG:** * **Dry Cough:** Occurs in ~10-15% of patients on ACEIs due to bradykinin and substance P accumulation in the lungs. * **First-line choice:** Both classes are first-line for Heart Failure (reduce remodeling) and Diabetic Nephropathy (reduce proteinuria). * **Hyperkalemia:** Both classes can cause hyperkalemia; monitor potassium levels closely.

Q: Which beta-blocker possesses peripheral vasodilator action?

Carvedilol. The correct answer is **Carvedilol**. Beta-blockers are classified into three generations based on their pharmacological properties. [1] Carvedilol is a **third-generation, non-selective beta-blocker** that also possesses **alpha-1 ($\alpha_1$) adrenergic receptor blocking activity**. [3] This dual action results in peripheral vasodilation, which reduces systemic vascular resistance and afterload. [1, 3] **Why the correct option is right:** * **Carvedilol:** By blocking $\beta_1$, $\beta_2$, and $\alpha_1$ receptors, it provides both cardiac protection and vasodilation. [3] It also possesses antioxidant and anti-proliferative properties, making it a cornerstone in the management of chronic heart failure. **Why the other options are incorrect:** * **Propranolol (Option A):** A first-generation, non-selective beta-blocker. [2] It lacks $\alpha$-blocking activity and may actually cause transient peripheral vasoconstriction due to unopposed $\alpha$-action when $\beta_2$ receptors are blocked. * **Atenolol (Option B):** A second-generation, cardioselective ($\beta_1$) blocker. It does not have vasodilatory properties. * **Acebutolol (Option D):** A second-generation, cardioselective blocker with **Intrinsic Sympathomimetic Activity (ISA)**. While it causes less bradycardia, it is not a direct peripheral vasodilator. **High-Yield Clinical Pearls for NEET-PG:** * **Third-Generation Vasodilatory Beta-blockers:** [1] * **Via $\alpha_1$ blockade:** Carvedilol, Labetalol. [3] * **Via Nitric Oxide (NO) release:** Nebivolol (most $\beta_1$ selective). * **Via $\beta_2$ agonism:** Celiprolol. * **Labetalol** is the drug of choice for hypertension in pregnancy (Preeclampsia). [1]

Q: All of the following can be used for the chronic oral treatment of arrhythmia except?

Esmolol. **Explanation:** The correct answer is **Esmolol** because of its unique pharmacokinetic profile. In the management of arrhythmias, the choice between oral and parenteral therapy depends on whether the goal is acute termination or chronic prophylaxis. **1. Why Esmolol is the correct answer:** Esmolol is an **ultra-short-acting**, cardioselective $\beta_1$ blocker. It is rapidly metabolized by **red blood cell esterases**, giving it an extremely short half-life of approximately **9 minutes**. Due to this rapid metabolism and its susceptibility to gastric acid, it cannot be administered orally. It is given exclusively via intravenous infusion for the acute management of supraventricular tachycardias (SVT), perioperative hypertension, or atrial fibrillation/flutter where rapid control is required. **2. Analysis of Incorrect Options:** * **Amiodarone (Class III):** Has a very long half-life (weeks to months) and is frequently used orally for the chronic maintenance of sinus rhythm in patients with atrial fibrillation or ventricular arrhythmias. * **Quinidine (Class IA):** An alkaloid that can be administered orally for the long-term prevention of SVT and ventricular tachycardia (though its use is declining due to side effects). * **Verapamil (Class IV):** A non-dihydropyridine calcium channel blocker available in oral formulations for the chronic rate control of atrial fibrillation and prevention of paroxysmal SVT. **Clinical Pearls for NEET-PG:** * **Esmolol "Rule of 9":** Half-life is ~9 minutes; full recovery from its effects occurs within ~20-30 minutes of stopping the infusion. * **Drug of Choice:** Esmolol is the preferred $\beta$-blocker for **Aortic Dissection** and **Thyroid Storm** during surgery due to its titratability. * **Safety:** Because of its short duration, if a patient develops bradycardia or hypotension, simply stopping the infusion resolves the side effects quickly.

Q: Which of the following is NOT a Class III antiarrhythmic agent?

Verapamil. **Explanation:** The classification of antiarrhythmic drugs is based on the **Vaughan-Williams classification**, which categorizes agents according to their primary mechanism of action on the cardiac action potential. **Why Verapamil is the correct answer:** Verapamil is a **Class IV antiarrhythmic agent**. Its primary mechanism is the blockade of L-type voltage-gated calcium channels. It acts predominantly on the SA and AV nodes, slowing conduction and prolonging the refractory period. It is used primarily for supraventricular tachycardias (SVT) and rate control in atrial fibrillation. **Analysis of Class III Agents (Incorrect Options):** Class III agents are **Potassium (K+) channel blockers**. They prolong Phase 3 repolarization, thereby increasing the Action Potential Duration (APD) and the Effective Refractory Period (ERP). * **Sotalol:** A unique agent with both non-selective beta-blocking (Class II) and K+ channel blocking (Class III) properties. * **Amiodarone:** A broad-spectrum agent that exhibits properties of all four Vaughan-Williams classes but is primarily categorized as Class III. * **Bretylium:** An older Class III agent (also a post-ganglionic adrenergic blocker) used historically for refractory ventricular fibrillation. **High-Yield NEET-PG Pearls:** * **Mnemonic for Class III:** "**A**id **I**s **D**octor **S**otalol" (**A**miodarone, **I**butilide, **D**ofetilide, **S**otalol). * **Amiodarone** contains iodine and is associated with pulmonary fibrosis, thyroid dysfunction (hypo/hyper), and corneal microdeposits. * **Reverse Use-Dependence:** A characteristic of Class III drugs (except Amiodarone) where their effect is more pronounced at slower heart rates, increasing the risk of **Torsades de Pointes**.

Q: Enalapril increases the level of which of the following?

Bradykinin. ### Explanation **Correct Option: C (Bradykinin)** **Mechanism:** Enalapril is an **Angiotensin-Converting Enzyme (ACE) Inhibitor**. The ACE enzyme (also known as Kininase II) has a dual function in the body: 1. It converts Angiotensin I to Angiotensin II (a potent vasoconstrictor). 2. It degrades **Bradykinin** (a potent vasodilator) into inactive metabolites. By inhibiting ACE, Enalapril prevents the breakdown of Bradykinin, leading to its accumulation in the tissues and blood. **Why the other options are incorrect:** * **A & B (Interferon and Growth factors):** ACE inhibitors do not have a direct or clinically significant effect on the systemic levels of interferons or growth factors. While ACE inhibitors may indirectly influence tissue remodeling (e.g., reducing cardiac hypertrophy), they do not "increase" these specific molecules as a primary pharmacological action. --- ### High-Yield Clinical Pearls for NEET-PG: * **The "Dry Cough" Connection:** The accumulation of Bradykinin and Substance P in the lungs is the primary cause of the characteristic **dry, hacking cough** seen in 5–20% of patients on ACE inhibitors. * **Angioedema:** Increased Bradykinin levels are also responsible for the rare but life-threatening side effect of angioedema. * **Switching Therapy:** If a patient develops a cough due to Enalapril, the best next step is to switch them to an **ARB (Angiotensin Receptor Blocker)** like Losartan, as ARBs do not inhibit Kininase II and thus do not increase Bradykinin. * **Active Form:** Remember that Enalapril is a **prodrug**; it must be converted by hepatic esterases into its active metabolite, **Enalaprilat**. (Lisinopril and Captopril are the exceptions—they are not prodrugs).

Q: Which of the following statements about Esmolol is true?

It is used in left ventricular decompensation.. **Explanation:** **Esmolol** is a unique, ultra-short-acting **beta-1 selective (cardioselective) blocker**. **Why Option D is Correct:** While beta-blockers are generally contraindicated in acute heart failure, Esmolol is specifically indicated for the management of **supraventricular tachyarrhythmias** or hypertension in patients with **left ventricular decompensation** (acute heart failure) or perioperative settings. Its "safety net" lies in its ultra-short duration of action; if the patient’s cardiac output drops further, the drug effect disappears within minutes of stopping the infusion, allowing for precise titration. **Analysis of Incorrect Options:** * **Option A:** Esmolol is a **Beta-blocker**, not an alpha-blocker. * **Option B:** It has an **extremely short half-life** (approximately 9 minutes). This is because it is rapidly hydrolyzed by **red blood cell esterases** (not by liver or kidney enzymes). * **Option C:** It is highly **cardioselective** (Beta-1 selective), making it safer for patients with reactive airway disease compared to non-selective blockers like Propranolol. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** Always given **Intravenously (IV)**; never orally. * **Metabolism:** Hydrolysis by RBC esterases (Unique feature). * **Indications:** Aortic dissection (to reduce shear stress), Thyroid storm, and perioperative tachycardia/hypertension. * **Mnemonic:** Remember **"Esmolol is Easy-off"** due to its rapid offset of action.

Q: A hypertensive patient is suffering from bilateral renal artery stenosis. Which of the following drugs should not be given?

Enalapril. **Explanation:** **Why Enalapril is the Correct Answer:** In patients with **bilateral renal artery stenosis (RAS)**, the renal perfusion pressure is significantly reduced. To maintain an adequate Glomerular Filtration Rate (GFR), the body relies on the **Renin-Angiotensin-Aldosterone System (RAAS)**. Specifically, Angiotensin II causes **vasoconstriction of the efferent arteriole**, which creates the necessary back-pressure to maintain filtration. **Enalapril**, an ACE inhibitor, blocks the formation of Angiotensin II. This leads to efferent arteriolar vasodilation, a sudden drop in intraglomerular pressure, and a subsequent precipitous fall in GFR, potentially leading to **acute renal failure**. Therefore, ACE inhibitors (and ARBs) are strictly contraindicated in bilateral RAS (or unilateral RAS in a solitary kidney). **Why Other Options are Incorrect:** * **B. Atenolol:** A beta-blocker that reduces blood pressure primarily by decreasing cardiac output and renin release. While it affects the RAAS, it does not cause the acute hemodynamic collapse of GFR seen with ACE inhibitors. * **C. Nifedipine:** A Calcium Channel Blocker (CCB) that acts as a peripheral vasodilator. It does not interfere with the efferent arteriolar tone and is generally considered safe in RAS. * **D. Hydrochlorothiazide:** A thiazide diuretic that reduces BP by decreasing blood volume. It does not have a specific adverse hemodynamic effect on the stenosed renal vasculature. **NEET-PG High-Yield Pearls:** * **Goldblatt Kidney:** The experimental model for renovascular hypertension. * **Diagnostic Clue:** Suspect RAS if a patient’s serum creatinine rises by **>30%** after starting an ACE inhibitor or ARB. * **Drug of Choice:** While ACE inhibitors are contraindicated in *bilateral* RAS, they are often the drug of choice for *unilateral* RAS (where the healthy kidney can compensate), provided renal function is monitored closely.

Q: Nitroglycerine exerts beneficial effects in classical angina pectoris primarily by:

Reducing cardiac preload. **Explanation:** **Mechanism of Action (The Correct Answer):** Nitroglycerine (NTG) is a potent venodilator. At therapeutic doses, it acts primarily on the large peripheral veins, increasing venous capacitance. This leads to **peripheral pooling of blood**, which decreases venous return to the heart. The resulting **reduction in cardiac preload** (Left Ventricular End-Diastolic Pressure) decreases ventricular wall tension and myocardial oxygen demand. Since angina occurs due to an imbalance between oxygen supply and demand, reducing the demand is the primary mechanism for relieving pain in classical angina. **Analysis of Incorrect Options:** * **Option A:** While NTG can dilate coronary arteries, it does not significantly increase *total* coronary blood flow in patients with atherosclerotic (classical) angina, as those vessels are often already maximally dilated by local metabolites. * **Option B:** NTG does redistribute blood flow from epicardial to **vulnerable subendocardial regions** by reducing LV wall tension, but this is secondary to the reduction in preload. * **Option D:** NTG only reduces afterload (arteriolar dilation) at high doses. Its primary clinical effect at standard doses is on the venous side (preload). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** NTG is the DOC for acute anginal attacks (Sublingual route due to high first-pass metabolism). * **Tolerance:** Continuous use leads to "tachyphylaxis" (depletion of free -SH groups). A **10-12 hour nitrate-free interval** is required daily. * **Monday Disease:** Workers in explosive factories develop tolerance during the week but lose it over the weekend, leading to headaches and tachycardia upon returning on Monday. * **Contraindication:** Never co-administer with **Sildenafil** (PDE-5 inhibitors) as it can cause life-threatening hypotension.

Q: Combination use of beta-blockers and calcium channel blockers can cause all of the following except:

Hypertension. ### Explanation The combination of **Beta-blockers (BBs)** and **Calcium Channel Blockers (CCBs)**, particularly the non-dihydropyridines like Verapamil and Diltiazem, results in synergistic depressant effects on the heart. **1. Why Hypertension is the Correct Answer (The "Except"):** Beta-blockers and CCBs both act to reduce blood pressure. Beta-blockers decrease cardiac output and renin release, while CCBs cause peripheral vasodilation and decrease cardiac contractility. Therefore, their combined use leads to **hypotension**, not hypertension. Using them together to treat hypertension requires extreme caution due to the risk of additive adverse effects on cardiac conduction. **2. Analysis of Incorrect Options:** * **Bradycardia & Heart Block:** Both BBs and non-dihydropyridine CCBs (Verapamil > Diltiazem) are **negative chronotropes** (decrease heart rate) and **negative dromotropes** (slow AV conduction). When used together, they can cause profound sinus bradycardia or precipitate high-grade AV block. * **Hypotension:** As both drug classes reduce the force of contraction (**negative inotropy**) and/or systemic vascular resistance, a significant drop in blood pressure is a common and expected side effect of the combination. **Clinical Pearls for NEET-PG:** * **The "Verapamil Rule":** Intravenous Verapamil is strictly contraindicated in patients already taking Beta-blockers due to the high risk of **asystole** or complete cardiovascular collapse. * **Safe Combination:** If a CCB must be added to a Beta-blocker, a **Dihydropyridine** (e.g., Amlodipine) is preferred because it has minimal effect on the SA/AV nodes and primarily acts on vascular smooth muscle. * **Drug of Choice:** Beta-blockers are the preferred treatment for CCB overdose (specifically for managing the resulting hyperglycemia and hypotension).

Question 1

Valsartan differs from ramipril in the following respect?

Accepted Answer

It does not potentiate bradykinin

Answer

It can be safely administered to a patient with bilateral renal artery stenosis

Answer

It impairs carbohydrate tolerance

Answer

It does not have fetopathic potential

Question 2

Which beta-blocker possesses peripheral vasodilator action?

Accepted Answer

Carvedilol

Answer

Propranolol

Answer

Atenolol

Answer

Acebutolol

Question 3

All of the following can be used for the chronic oral treatment of arrhythmia except?

Accepted Answer

Esmolol

Answer

Amiodarone

Answer

Quinidine

Answer

Verapamil

Question 4

Which of the following is NOT a Class III antiarrhythmic agent?

Accepted Answer

Verapamil

Answer

Sotalol

Answer

Amiodarone

Answer

Bretylium

Question 5

Enalapril increases the level of which of the following?

Accepted Answer

Bradykinin

Answer

Interferon

Answer

Growth factors

Answer

All of the above

Question 6

Which of the following statements about Esmolol is true?

Accepted Answer

It is used in left ventricular decompensation.

Answer

It is an alpha blocker.

Answer

It has a long half-life.

Answer

It is not cardioselective.

Question 7

Which of the following statements regarding ACE inhibitors is TRUE?

Accepted Answer

Omission of prior diuretic dose decreases the risk of postural hypotension

Answer

These inhibit the conversion of angiotensinogen to angiotensin I

Answer

Lisinopril is shorter acting than enalapril

Answer

These are contraindicated in diabetic patients.

Question 8

A hypertensive patient is suffering from bilateral renal artery stenosis. Which of the following drugs should not be given?

Accepted Answer

Enalapril

Answer

Atenolol

Answer

Nifedipine

Answer

Hydrochlorothiazide

Question 9

Nitroglycerine exerts beneficial effects in classical angina pectoris primarily by:

Accepted Answer

Reducing cardiac preload

Answer

Increasing total coronary blood flow

Answer

Redistributing coronary blood flow

Answer

Reducing cardiac afterload

Question 10

Combination use of beta-blockers and calcium channel blockers can cause all of the following except:

Accepted Answer

Hypertension

Answer

Heart block

Answer

Hypotension

Answer

Bradycardia

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?